Geftinat

Geftinat (Gefitinib) is classified as a protein kinase inhibitor and is indicated for the treatment of non-small cell lung cancer. Its mechanism of action is inhibiting the signaling pathways responsible for causing the growth of cancer cells. When normal cell growth is affected, constant division of cells can occur, which in turn may lead to lung cancer. It is common for an increase in epidermal growth factor receptor (EFGR) activity to occur in tumors (usually due to mutations within the EFGR causing a mutated EGF receptor), which contributes to the proliferation of cancer cells and the growth of the tumor.

This medication works by binding to the tyrosine kinase domain of the mutated EFGR and blocking its signaling pathways. As a result of this, the spread and multiplication of the cancer cells may be stopped. It should be noted that this medicine is only used for the treatment of EFGR mutation positive non-small cell cancer, and diagnostic tests may be required by the physician providing treatment to determine whether or not the cancer is likely to respond to treatment with this medication.

Geftinat (Gefitinib) comes as 250mg strength tablets which are to be taken by mouth. Patients will be placed under the close supervision of a physician at all times during treatment. Generally, physicians will instruct adult patients to take 1 tablet per day. Patients may swallow the tablet alongside a glass of water, and it may be administered either with or without food. In some cases, patients who suffer from side effects due to toxicity may be directed by their physician to take a short break from treatment which may last for as long as 14 days, before continuing treatment. All instructions provided by the physician responsible for treatment must be followed at all times.

Patients taking the protein kinase inhibitor Geftinat (Gefitinib) may experience some side effects. Report all reactions to your physician. Possible examples include:

• Acne
• Nausea
• Itchiness
• Loss of body weight
• Dryness affecting the skin

Other reactions that have not been listed above are also possible. Get medical attention or consult your physician immediately if you suffer from nosebleeds, blood present in the urine, pain or irritation occurring in the eyes, abnormal eyelash growth, visual disturbances or any other severe adverse events that have not been referenced here.

Blood tests will be ordered by your physician during the course of treatment with Geftinat (Gefitinib) tablets, so that your liver function can be monitored.

This medication should not be taken by pregnant women as it may cause harm to the unborn baby. Birth control will be required during treatment. Breastfeeding should also be avoided by women taking this medicine.

Should you notice signs of a cough that is getting worse, it will be necessary to inform your physician immediately. This is because there is a risk of interstitial lung disease associated with this medicine.